Cardiometabolic risk assessment: An approach to the prevention of cardiovascular disease and diabetes mellitus

Clinical Cornerstone

Volumn 7, Issue 2-3, 2005, Pages 7-16

  Vasudevan, Abu R ^a,b   Ballantyne, Christie M ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; ENERGY BALANCE; EPIDEMIC; HIGH RISK PATIENT; HYPERGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE; MEDICAL SOCIETY; METABOLIC SYNDROME X; OBESITY; PATHOGENESIS; PRACTICE GUIDELINE; RISK ASSESSMENT; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; METABOLIC SYNDROME X; OBESITY; PRACTICE GUIDELINES; REFERENCE STANDARDS; RISK; RISK ASSESSMENT;

EID: 32144442853     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(05)80063-8     Document Type: Article

References (47)

1. American Heart Association Heart Disease and Stroke Statistics - 2005 Update 2005 American Heart Association Dallas, Tex
2. Centers for Disease Control and Prevention, NationalCenter for Chromic Disease Prevention and Health Promotion. Preventing heart disease and stroke. Available at: http://www.cdc.gov/nccdphp/bbheartdisease/index.htm
3. Centers for Disease Control and Prevention, NationalCenter for Chromic Disease Prevention and Health Promotion. National Diabetes Surveillance System: Prevalence of diabetes. Tvailable at: http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm.
4. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. National diabetes statistics. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm.
5. Flegal K.M. Carroll M.D. Ogden C.L. Johnson C.L. Prevalence and trends im obesity among US adults, 1999-2000 JAMA 288 2002 1723-1727
6. Kannel W.B. McCe D.L. Diabetes and cardiovascular disease: The Framingham study JAMA 241 1979 2035-2038
7. Pyorala K. Laakso M. Uusitupa M. Diabetes and atherosclerosis: Am epidemiologic view Diabetes Metab Rev 3 1987 463-524
8. (Suppl) Laakso M. Lehto S. Epidemiology of risk factors for cardiovascular disease im diabetes and impaired glucose tolerance Atherosclerosis 137 1998 S65-S73
9. Haffner S.M. Lehto S. Rönemaa T. et al. Mortality from coronary heart disease im subjects with type 2 diabetes and im nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229-234
10. (Suppl) Turner R.C. Holman R.R. Lessons from UK Prospective Diabetes Study Diabetes Res Clin Pract 28 1995 S151-S157
11. Haffner S.M. Stern M.P. Hazuda H.P. et al. Cardiovascular risk factors im confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset ofclinical diabetes? JAMA 263 1990 2893-2898
12. Kylin E. Studien ber das Hypertonie-Hyperglykanie-Hyperurikaniesyndrom Zentralblatt für Innere Medizin 44 1923 105-127
13. Reaven M. Banting Lecture 1988. Role of insulin resistance im human disease Diabetes 37 1988 1595-1607
14. Alberti K.G. Zimmet PZ Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetesmellitus provisional report of a WHO consultation Diabet Med 15 1998 539-553
15. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol im Adults. Executive summary of the third report of the NationalCholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol im Adults (Adult Treatment Panel III) JAMA 285 2001 2486-2497
16. Gundy S.M. Cleeman I. Daniels S.R. et al. Diagnosis and management of the metabolic syndrome: Am American Heart Association/National Heart, Lung, and Blood InstituteScientific Statement Circulation 112 2005 2735-2752
17. Unwin N. Shaw J. Zimmet P. Alberti K.G. Impaired glucose tolerance and impaired fasting glycaemia: The current status on definition and intervention Diabet Med. 19 2002 708-723
18. Alberti K.G. Zimmet P. Shaw J. The metabolic syndrome a new worldwide definition Lancet 366 2005 1059-1062
19. Liese A.D. Mayer-Davis E.J. Haffner S.M. Development of the multiple metabolic syndrome: Am epidemiologic perspective Epidemiol Rev 20 1998 157-172
20. [Epub ahead of print]. Aizawa Kamimura N. Watanabe H. et al. Cardiovascular risk factors are really linked im the metabolic syndrome: This phenomenon suggests clustering rather than coincidence Int J Cardiol II 2005 12
21. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence Diabetes Care 28 2005 1769-1778
22. McNeill A.M. Rosamond W.D. Gman C.J. et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities study Diabetes Care 28 2005 385-390
23. Isomaa B. Almgren P. Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome Diabetes Care 24 2001 683-689
24. Hanson R.L. Imperatore G. Bennett P.H. Knowler W.C. Components of the "metabolic syndrome" and incidence of type 2 diabetes Diabetes 51 2002 3120-3127
25. Laaksonen D.E. Lakka H.M. Niskanen L.K. et al. Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested defini tions of the metabolic syndrome ima prospective cohort study Am J Epidemiol 156 2002 1070-1077
26. Schmidt M.I. Duncan B.B. Bang H. et al. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk im Communities study Diabetes Care 28 2005 2013-2018
27. Zu S. Wang Z. Heshka S. et al. Waist circumference and obesity-associated risk factors among whites im the Third National Health and Nutrition Examination Survey: Clinical action thresholds Am J Clin Nutr 76 2002 743-749
28. Pouliot M.C. Despres P. Lemieux S. et al. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tis sue accumulation and related cardiovascular risk im men and women Am J Cardiol 73 1994 460-468
29. Lemieux I. Pascot A. Couillard C. et al. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) im men? Circulation 102 2000 179-184
30. Poirier P. Despres P. Waist circumference, visceral obesity, and cardiovascular risk J Cardiopulm Rehabil 23 2003 161-169
31. Diamant M. Lamb H.J. van de Ree M.A. et al. The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers imuncomplicated type 2 diabetes J Clin Endocrinol Metab 90 2005 1495-1501
32. Katzmarzyk P.T. Church T.S. Inssen I. et al. Metabolic syndrome, obesity, and mortality: Impact of cardiorespiratory fitness Diabetes Care 28 2005 391-397
33. Khaw K.T. Wareham N. Luben R. et al. Cycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) BMJ 322 2001 15-18
34. Hu F.B. Stampfer M.J. Haffner S.M. et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes Diabetes Care 25 2002 1129-1134
35. Coutinho M. Crstein H.C. Wang Ysuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years Diabetes Care 22 1999 233-240
36. DECODE Study Group on behalf of the European Diabetes Epidemiology Group Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 26 2003 688-696
37. Chobanian A.V. Bakris G. Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The NC 7 report JAMA 289 2003 2560-2572
38. Pan X.R. Li G.W. Hu M. et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qg ITG and Diabetes Study Diabetes Care 20 1997 537-544
39. Torjesen P.A. Birkeland K.I. Anderssen S.A. et al. Lifestyle changes may reverse development of the insulin resistance syndrome: The Oslo Diet and Exercise Study:A random ized trial Diabetes Care 20 1997 26-31
40. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393-403
41. Deedwania P.C. Fonseca V.A. Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm Am J Med. 118 2005 939-947
42. Chiasson L. Josse R. Gomis R. et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial Lancet 359 2002 2072-2077
43. Orchard T.J. Temprosa M. Goldberg R. et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program randomized trial Ann Intern Med 142 2005 611-619
44. American Diabetes Association Standards of medical care in diabetes Diabetes Care 28 2005 S4-S36
45. Stern M.P. Williams K. Haffner S.M. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136 2002 575-581
46. McNeely M.J. Boyko E.J. Leonetti D.L. et al. Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes risk in Japanese Americans Diabetes Care 26 2003 758-763
47. Lindstrom J. Tuomilehto J. The diabetes risk score: A practical tool to predict type 2 diabetes risk Diabetes Care 26 2003 725-731